The Tokyo stock market opened with a sharp retreat in the week to March19, led by heavy losses in global equity markets. However, the market rebounded mid-week, triggered by remarks from Japan's Finance Minister and the govenor of the Bank of Japan on policy measures to revitalize the market. The Nikkei 225 closed the week with a 0.2% gain, recovering from Tuesday's below-12,000 level, the lowest in 16 years. The Topix index dipped only 0.5%.
The Finance Minister commented that public funds could be used to cover losses incurred by the proposed private-sector fund for purchasing equities from corporations. Also, the BoJ's governor suggested a further easing of monetary policy in view of the fact that the economy is in a state of deflation, with two-year consecutive declines in consumer and wholesale prices. In fact, at the end of the week, the BoJ's Policy Board decided on quantitative credit easing steps to provide increased funds to the financial market.
This policy is expected to lower the overnight call rate to zero, representing the virtual revival of "zero-interest-rate" policy. In response, financial stocks were bought, while technology issues continued to meet selling pressure in view of the further retreat of the US Nasdaq. The market waits to see implementation of the concrete measures in the emergency economic package proposed in the previous week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze